Adults with a specific type of aggressive lung cancer that had stopped responding to platinum chemotherapy now have a new oral treatment option. The FDA granted accelerated approval to sunvozertinib, sold as Zegfrovy, for patients with locally advanced or metastatic non-small cell lung cancer driven by EGFR exon 20 insertion mutations. In the clinical trial supporting the decision, the drug produced a 46 percent objective response rate, a significant result for a patient population that has historically had few targeted therapies available after standard treatment fails.
An oral option for a mutation with limited targeted treatments
EGFR exon 20 insertion mutations account for a small but stubborn subset of non-small cell lung cancers. These tumors resist most first-line EGFR inhibitors designed for more common mutations, leaving patients dependent on platinum-based chemotherapy as an early treatment. When that chemotherapy stops working, the options narrow fast. The FDA had previously approved the infused antibody amivantamab-vmjw for this same mutation, but that drug requires intravenous administration, which means regular clinic visits, infusion-related reactions, and scheduling burdens that can wear on patients already managing advanced disease.
Sunvozertinib is a pill. That distinction matters beyond convenience. For patients whose cancer has progressed after platinum chemotherapy, the ability to take a daily oral medication at home rather than traveling to an infusion center could translate into better day-to-day adherence and fewer treatment interruptions. Whether that advantage shows up in real-world prescription and discontinuation data will take time to confirm, but the practical difference between swallowing a tablet and sitting for an infusion is already clear to oncologists managing this population. The approval effectively gives doctors a second targeted agent for post-platinum EGFR exon 20 patients, and the first one that does not require a needle.
The WU-KONG1 trial and the 46 percent response rate
The approval rests on results from the WU-KONG1 study, a multi-cohort trial evaluating sunvozertinib in advanced NSCLC patients with EGFR or HER2 mutations. According to the trial registry, WU-KONG1 enrolled adults with locally advanced or metastatic disease who had received prior systemic therapy and carried specific genomic alterations, including EGFR exon 20 insertions. The FDA reviewed data from the WU-KONG1B component, which focused specifically on patients with EGFR exon 20 insertion mutations whose disease had progressed on or after platinum-based chemotherapy.
In that cohort, the agency reported an objective response rate of 46 percent, meaning nearly half of the patients in the study saw their tumors shrink measurably. Responses included both partial and complete tumor regressions as assessed by independent review. For many patients, tumor shrinkage was accompanied by relief of symptoms such as cough, shortness of breath, or pain, although those clinical details are less systematically captured than radiographic outcomes.
That number carries weight when compared to the broader treatment picture for this mutation. Before targeted agents entered the space, response rates in the post-platinum setting were considerably lower, often in the teens or single digits with conventional chemotherapy. The 46 percent figure signals that sunvozertinib is engaging its target and altering disease biology in a way that standard regimens typically do not achieve for this subgroup. It also suggests that, for a meaningful fraction of patients, the drug can temporarily regain control over tumors that have already demonstrated resistance to frontline therapy.
The approval came through the FDA’s accelerated pathway, which allows drugs to reach patients based on surrogate endpoints like response rate before longer-term survival data are fully mature. This mechanism has been used repeatedly in oncology when unmet need is high and early efficacy signals are strong. The agency has applied the same framework to other recent lung cancer decisions, including the accelerated approval of tarlatamab-dlle for extensive-stage small cell lung cancer, where the DeLLphi-301 trial showed a 40 percent objective response rate with a median duration of response of 9.7 months, as summarized in the regulatory announcement.
These parallel approvals reflect a pattern: the FDA is willing to move quickly on targeted drugs for hard-to-treat lung cancers when early trial data show meaningful tumor shrinkage, even before overall survival benefits are confirmed. Tarlatamab, for its part, represented the first DLL3-targeting bispecific T-cell engager approved for lung cancer, according to reporting in Nature Reviews Drug Discovery. Sunvozertinib now joins that wave as a next-generation EGFR inhibitor tailored to an especially challenging mutation. Each of these decisions expands the toolkit for oncologists, but each also carries the condition that confirmatory trials must follow.
Missing survival data and the confirmatory trial requirement
The central gap in the evidence is straightforward: the FDA approved sunvozertinib based on how often tumors shrank, not on how long patients lived. Overall survival data from the WU-KONG1 program have not been reported in the primary FDA documents or the ClinicalTrials.gov registry entry. Progression-free survival and quality-of-life outcomes are also still emerging. That is not unusual for accelerated approvals, but it means the drug’s long-term benefit is unproven and must be verified in subsequent studies.
To manage that uncertainty, the FDA routinely attaches postmarketing requirements to accelerated approvals. The agency maintains a public tracker of ongoing oncology commitments, listing the confirmatory trials sponsors must conduct to demonstrate clinical benefit. For sunvozertinib, the sponsor will be expected to show that gains in tumor response translate into longer survival or at least more durable disease control compared with existing options such as amivantamab or chemotherapy. If future data fail to confirm a benefit, the FDA has the authority to withdraw the indication.
That dynamic is not hypothetical. In recent years, several cancer drugs that entered the market through the accelerated pathway have later had indications revised or removed when confirmatory studies did not meet their primary endpoints. The system is designed to balance early access with scientific rigor: patients with few options can receive promising therapies sooner, but the bar for staying on the market is higher than simply reproducing response rates in additional single-arm trials.
For clinicians and patients, the absence of mature survival data introduces a familiar trade-off. On one hand, sunvozertinib offers a statistically robust chance of tumor shrinkage and the convenience of oral dosing, both highly relevant in a population facing progressive, symptomatic disease. On the other, the magnitude of any survival advantage, the durability of responses beyond the median, and the full spectrum of long-term toxicities remain uncertain. Shared decision-making will need to incorporate that nuance, particularly for patients who may be candidates for clinical trials of other emerging agents.
What the approval means for patients and practice
In practical terms, the sunvozertinib approval reshapes the treatment algorithm for EGFR exon 20 insertion–positive NSCLC after platinum chemotherapy. Oncologists now have a choice between an intravenous antibody and an oral tyrosine kinase inhibitor, each with distinct toxicity profiles, logistical demands, and potential advantages. For some patients, especially those living far from infusion centers or juggling work and caregiving responsibilities, the ability to take a pill at home could be decisive.
The decision may also influence molecular testing patterns. Knowing that there is now more than one targeted option for EGFR exon 20 insertions could encourage broader adoption of comprehensive genomic profiling at diagnosis, ensuring that patients with these relatively rare mutations are identified early and can be steered toward the most appropriate therapies as their disease evolves. As confirmatory data accumulate, guidelines are likely to refine where sunvozertinib fits relative to other treatments, including whether it might eventually move into earlier lines of therapy.
For now, the approval underscores both progress and unfinished work. A once-overlooked molecular subset of lung cancer has gained a tailored oral therapy with clear antitumor activity, yet the field still awaits definitive evidence on survival and long-term outcomes. How quickly those answers arrive-and whether they match the promise of the early response data-will determine whether sunvozertinib remains a fixture in the lung cancer arsenal or serves as a stepping stone toward even more effective targeted strategies.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
